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The prevalence of helminthic infections in most of the
developing countries is overwhelming, and almost a quarter of
the world’s population is infected by them. Likewise, with the
spread of the AIDS epidemic, dual helminthic and HIV-1
coinfections are extremely common, particularly in Africa [1].
Several years ago we suggested that helminth infections play a
major role in the pathogenesis of HIV-1 infection in Africa and
other developing countries, due to their profound effects on the
host immune system, which would make those infected with
helminths more susceptible to HIV-1 infection and more
vulnerable to the disease’s effects [2]. As summarized in three
more recent reviews, we and others have demonstrated that
chronic immune activation with a dominant T helper cell 2 profile,
and anergy, are indeed the hallmarks of chronic helminth infection
[3–5]. These immune changes are characterized by several
modulations in the normal immune response, particularly those
of the cellular immune response, which together could account for
possible profound effects of the chronic helminthic infection on the
host’s ability to handle HIV as well as other infections.
Importantly, most of these modulations are reverted almost
completely to normal following treatment of the helminthic
infections.
Several studies have since lent further support to this
association: (i) T cells and monocytes obtained from helminth-
infected individuals have increased expression of HIV-1 chemo-
kine coreceptors [6–8]; (ii) peripheral blood mononuclear cells
obtained from helminth-infected individuals are more susceptible
to HIV-1 infection, and the increased susceptibility is correlated to
the chronic immune activation of the cells [9,10]; (iii) the risk of
mother-to-child HIV-1 transmission in pregnant women coinfect-
ed with one or more helminths was found to be significantly higher
than in women without helminth infections [11]; (iv) an association
was found between genital lesions caused by Schistosoma haematobium
infection in women and susceptibility to HIV infection [12]; and
(v) people coinfected with HIV and S. mansoni have decreased
CD8
+ cytolytic HIV-1-specific T cell responses and increased
interleukin-10 production compared to individuals infected with
HIV-1 only [13].
Perhaps more compelling with regard to the effect helminth
infection may have on HIV infection are the results of recent
studies in primates dually infected with Schistosoma and simian-
human immunodeficiency virus (SHIV), which show that: (i)
Schistosoma-infected monkeys required significantly less SHIV to
become infected with the virus in comparison to Schistosoma-
noninfected animals [14]; (ii) primates infected with S. mansoni,
when acutely infected with SHIV, developed higher levels of
plasma SHIV in comparison with Schistosoma-noninfected animals,
and regardless of the intensity of the parasite infection; (iii ) re-
exposure to Schistosoma of monkeys infected with SHIV resulted in
additional significant increase of the SHIV viral load [14,15]; and
(iv) primates chronically infected with SHIV, when also infected
with Schistosoma, showed a significant increase of SHIV plasma
viral load together with a decrease in the percentage of their
CD4(
+) CD29(
+) memory cells [16].
With this background, Walson and John-Stewart have per-
formed a systematic review of the literature on studies determining
the effects of treatment of helminth coinfection in HIV-1-infected
individuals, which is published in this issue [17]. They identified
6,384 relevant citations of which only 15 were identified as
potentially relevant studies; at last only five studies were found
eligible for inclusion based on the HIV/AIDS Cochrane Review
Group search strategy and guidelines. Most studies were not
included due to inadequate reporting or collection of data, lack of
a control comparison group, and failure to confirm helminth
infection status. Among the five studies finally included in the
analysis, only one is a single randomized controlled trial and the
other four are observational studies. As a result of their analysis,
Walson and John-Stewart conclude that despite the void in
conclusive evidence demonstrating the efficacy of anti-helminth
treatment in slowing HIV-1 disease progression, there is a positive
outcome in regard to the correlation between helminth infection
treatment and HIV plasma viral load decrease (though no
correlation was observed with other relevant parameters, such as
CD4 T cell counts) in the five very carefully reviewed studies. The
fact that only five studies, out of over 6,000 reviewed studies
addressing this issue, were finally included in the analysis clearly
illustrates the paucity of good studies in this area. Furthermore,
even within this small group of studies, significant differences in
methodology and evaluation are evident, and therefore conflicting
results are not surprising (let alone the lack of significant effects of
deworming on CD4 levels). Thus, Walson and John-Stewart
rightly conclude from their review that there is an urgent need for
larger and wider studies of this question, and that they should be
preferably double-blinded and well controlled. It is of interest to
note that since the time the review has been performed there has
been one additional report of a study performed in Tanzania,
which showed significant effects of eradication of filarial infection
on plasma HIV viral load decrease [18].
While overall we fully agree with these conclusions, we wish to
re-emphasize two major issues. First, given that the immune
changes accompanying helminth infections are profound and
universal, and more importantly, that they revert to normal after
eradication of the helminth infection, their role in the interaction
between the host and the other infections cannot be overempha-
sized and should therefore be adequately addressed in any future
design of studies on treatment of helminths in dual infection with
HIV. Second, helminth infections have an ongoing prolonged and
wide negative effect on the health of the population, irrespective of
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control of helminths should be pursued in large parts of the
developing world without delay and should not await the results of
studies on the impact of helminths on HIV or other infections.
Moreover, since control of all neglected tropical diseases has
become a feasible and attainable objective, and is now offered as a
‘‘package’’ treatment [19], its wide application can even take
precedence over studies on the specific effects of deworming on
HIV viral load. Taking this broad approach may still help
determine the effects deworming will have on the epidemiology
and spread of HIV and other infections, as well as shedding
further light on the role of host immunity in this interaction and on
susceptibility to HIV infection. Lastly, such an approach does not
have to exclude any well-designed and large-scale studies that will
address specific issues referred to above, as Walson and John-
Stewart recommend.
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